Vimarsana
Biggest News Aggregation in the World

Page 13 - Poster Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Presentation Today - Breaking & Trending Today

Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO - Vimarsana News

Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress - Vimarsana News

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023Announced Clinical Supply Agreement with Roche to Evaluate... | May 4, 2023

Central University of Odisha Project Fellow received Poster Award- 2023 - Vimarsana News

Central University of Odisha Project Fellow received Poster Award- 2023

Koraput: Ms. Monali Nanda, Project Fellow of the Department of Biodiversity and Conservation of Natural Resources, Central University of Odisha, was conferred with Poster Presentation Award- 2023 in the National Conference on ‘Plant Tissue Culture: A

Research plays important role in solving S&T problems: Jharkhand Governor - Vimarsana News

Research plays important role in solving S&T problems: Jharkhand Governor

Research plays important role in solving S&T problems: Jharkhand Governor | Jamshedpur News | The Avenue Mail

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL) - Vimarsana News

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated ... | April 17, 2023